Initial contract includes 100 Low-Cost Tactical ISR UAS systems, with options for Canadian Armed Forces to acquire up to 4,900 additional systems

Calgary, Alberta, Sept. 11, 2026 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading developer of drone solutions and systems, today announced that it has been awarded a five-year contract by the Government of Canada to provide Low-Cost Tactical Intelligence, Surveillance and Reconnaissance (“ISR”) Uncrewed Aircraft Systems (“UAS”) to the Canadian Armed Forces (“CAF”).

The initial contract includes a firm commitment for 100 Low-Cost Tactical ISR UAS systems, together with associated ground control stations, payloads, data links, support equipment, documentation, spare parts and training. Contracted pricing for the systems is commercially sensitive.

Under the five-year agreement, the Government of Canada has retained the right, at its sole discretion, to order up to an additional 4,900 UAS systems. If all available options were exercised, the total number of UAS systems supplied under the agreement to the Government of Canada would be 5,000. The contractual option for the additional 4,900 UAS systems has an aggregate value of approximately C$24.25 million if exercised in full. Any exercise of those options would require the appropriate written contract authorization or amendment.

The contract also includes initial cadre training for CAF personnel and provides Canada with options for additional training. Draganfly will support the program across system delivery, training, sustainment, spare parts, documentation, software and firmware support.

Draganfly was recently accepted as a qualified supplier in all five categories of Canada’s Defence Drone Initiative (“DDI”) Marketplace. This contract represents a subsequent procurement by the Government of Canada under the initiative and advances Draganfly’s participation in Canada’s expanding domestic defence and uncrewed systems ecosystem.

“This award is an important milestone for Draganfly and a meaningful opportunity to support the Canadian Armed Forces with systems designed to be fielded, supported and scaled in response to real operational requirements,” said Cameron Chell, President and CEO of Draganfly. “Canada is moving quickly to strengthen its sovereign defence capabilities and domestic industrial base. We are proud that Draganfly’s technology and team have been selected to contribute to that effort and look forward to delivering these systems into the hands of Canadian operators.”

Canada’s Defence Drone Initiative is intended to accelerate access to Canadian-developed uncrewed and autonomous capabilities while strengthening the country’s domestic defence industrial base. Low-cost tactical ISR drones are one of the initiative’s initial priority areas, with a focus on secure and affordable systems that can be widely deployed, field-tested and adapted based on operator requirements.

About Draganfly

Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8) is a leader in cutting-edge drone solutions and software that are transforming industries and serving stakeholders globally. Recognized for innovation and excellence for over 25 years, Draganfly delivers award-winning technology to the public safety, civil, military, agriculture, industrial inspection, security, mapping, and surveying markets. The Company is driven by passion, ingenuity, and a mission to provide efficient solutions and first-class services to customers worldwide, saving time, money, and lives.

For more information, visit www.draganfly.com.

For investor details, visit:
NASDAQ (DPRO)
CSE (DPRO)
FSE (3U8)

Media Contact
Erika Racicot
Email: media@draganfly.com

Company Contact
Cameron Chell
Chief Executive Officer
(306) 955-9907
Email: info@draganfly.com

Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements in this release include, but are not limited to: the aggregate number of UAS systems CAF will order based on exercises of options; that Draganfly expand will role in Canada’s Defence Industrial Strategy. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: statements in respect of Draganfly’s partnerships, capabilities, expertise, and financial condition; the successful integration of technology, the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties disclosed under the heading “Risk Factors“ in the Company’s most recent filings filed with securities regulators in Canada on the SEDAR+ website at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on the EDGAR website at www.sec.gov.

The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements’ best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

WARRENVILLE, Ill., Sept. 11, 2026 (GLOBE NEWSWIRE) — Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today announced the award of multiple air pollution control (APC) contracts valued at approximately $2.8 million for utility and industrial customers.

An order was secured for a urea reagent delivery system for a new U.S. utility customer adding new natural gas-fired turbines and reciprocating engines as part of a power plant expansion. The scope is to supply the urea reagent delivery systems to support Selective Catalytic Reduction (SCR) systems to reduce nitrogen oxide (NOx) emissions to meet the site requirements. The urea system eliminates the hazards associated with the transport, storage and handling of anhydrous or aqueous ammonia. Fuel Tech will commence engineering work immediately with equipment delivery expected in the third quarter of 2027.  

Two separate awards were received for electrostatic precipitator (ESP) performance modeling services from new domestic and international customers. The ESP modeling incorporates a suite of interdependent computer models into a Numerical Electrostatic Precipitation (NEP) model, which quickly and economically identifies the available upgrade options that can help improve ESP performance and achieve compliance with new and emerging particulate environmental regulations.  Both modeling contracts are expected to be completed in the fourth quarter of 2026.

A contract was also secured from a repeat domestic customer to demonstrate Selective Non-Catalytic Reduction (SNCR) technology on a waste incinerator unit. Fuel Tech’s SNCR technology is a proven solution for industrial combustion unit owners looking to comply with more stringent NOx control requirements. The demonstration is scheduled for the third quarter of 2026 and, subject to a successful outcome, permanent equipment orders could be secured in the fourth quarter of 2026.

“We are pleased to announce these contract awards and upcoming demonstration that support the needs of our diverse customer base. These orders bring us to $15 million in announced bookings year-to-date, and an effective backlog of $20 million. We are continuing to actively pursue additional APC contracts that are likely to be awarded in the next 60-90 days. We continue to see growth in 2026 with our core products and services as we look towards future strategic growth opportunities,” said Ramesh Nuggihalli, President and CEO.

About Fuel Tech

Fuel Tech develops and commercializes state-of-the-art proprietary technologies for air pollution control, process optimization, water treatment, and advanced engineering services. These technologies enable customers to operate in a cost-effective and environmentally sustainable manner. Fuel Tech is a leader in nitrogen oxide (NOx) reduction and particulate control technologies, and its solutions have been installed on over 2,100 utility, industrial and municipal units worldwide. The Company’s chemical technologies improve the efficiency, reliability, fuel flexibility, boiler heat rate, and environmental status of combustion units by controlling slagging, fouling, corrosion and opacity. This includes Fuel Tech’s advanced TIFI® Targeted In-Furnace Injection™ technology which offers an innovative solution to fireside treatment on boilers using coal, oil or biomass. Water treatment technologies include DGI® Dissolved Gas Infusion Systems which utilize a patented saturator and a patent-pending channel injector to deliver supersaturated oxygen solutions and other gas-water combinations to target process applications or environmental issues. This infusion process has a variety of applications in the water and wastewater industries, including remediation, aeration, biological treatment and wastewater odor management. Many of Fuel Tech’s products and services rely heavily on the Company’s exceptional Computational Fluid Dynamics modeling capabilities, which are enhanced by internally developed, high-end visualization software. For more information, visit Fuel Tech’s web site at ftek.com.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” as defined in Section 21E of the Securities Exchange Act of 1934, as amended, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and reflect Fuel Tech’s current expectations regarding future growth, results of operations, cash flows, performance and business prospects, and opportunities, as well as assumptions made by, and information currently available to, our management. Fuel Tech has tried to identify forward-looking statements by using words such as “anticipate,” “believe,” “plan,” “expect,” “estimate,” “intend,” “will,” and similar expressions, but these words are not the exclusive means of identifying forward-looking statements. These statements are based on information currently available to Fuel Tech and are subject to various risks, uncertainties, and other factors, including, but not limited to, those discussed in Fuel Tech’s Annual Report on Form 10-K in Item 1A under the caption “Risk Factors,” and subsequent filings under the Securities Exchange Act of 1934, as amended, which could cause Fuel Tech’s actual growth, results of operations, financial condition, cash flows, performance and business prospects and opportunities to differ materially from those expressed in, or implied by, these statements. Fuel Tech undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances or for any other reason. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including those detailed in Fuel Tech’s filings with the Securities and Exchange Commission.

CONTACT:    Devin Sullivan
                      Managing Director
                      The Equity Group Inc.
                      devin.sullivan@theequitygroup.com

Mandeep Chawla named to newly created role of Group President, Global Markets;
Todd Ankenmann appointed to Chief Financial Officer

TORONTO, Sept. 11, 2026 (GLOBE NEWSWIRE) — Celestica Inc. (NYSE, TSX: CLS), a global leader in data center infrastructure and advanced technology solutions, today announced executive leadership appointments to align with the company’s strong growth trajectory and position the business for sustainable, multi-year growth. Effective October 1, 2026, Mandeep Chawla will assume the newly created role of Group President, Global Markets, and Todd Ankenmann will succeed him as Chief Financial Officer (CFO).

In the new role of Group President, Global Markets, Chawla will oversee the company’s overarching commercial execution and global market expansion. This structure is designed to drive operational velocity, scale the business effectively and capture accelerating demand across Celestica’s end markets.

Chawla has served as Celestica’s CFO since 2017, playing a critical role in driving the company’s financial health, strategic transformation, and long-term performance. Prior to joining Celestica in 2010, Chawla spent nearly a decade at General Electric (GE), followed by senior leadership roles across the engineering and life sciences sectors.

“Celestica is experiencing unprecedented growth, and as we look to the future, we are evolving our leadership structure to ensure we can scale effectively and continue delivering exceptional value to our customers and shareholders,” said Rob Mionis, Chairman and Chief Executive Officer, Celestica. “Mandeep has been an outstanding CFO and a core contributor to our strategic vision. His deep understanding of our business, combined with his exceptional commercial acumen, makes him the ideal leader to step into this crucial new role to drive our next chapter of growth.”

Succeeding Chawla as CFO is Todd Ankenmann, who brings a wealth of institutional knowledge and financial expertise to the executive team. Ankenmann joined Celestica in 2018 and currently serves as Senior Vice President, Finance, where he plays a pivotal role in strategic planning, financial reporting, and commercial execution. Before joining Celestica, Ankenmann spent over a decade in senior finance leadership roles at GE.

“With his deep understanding of our business model, rigorous financial management, and proven track record across our ATS and CCS businesses, Todd is uniquely positioned for a seamless transition to Chief Financial Officer,” said Mionis. “Together, these appointments optimize our executive team to deliver on our long-term growth objectives.”

About Celestica
Celestica is a technology leader dedicated to driving customer success and market advancements. With deep expertise in design, engineering, manufacturing, supply chain, and platform solutions, Celestica enables critical data center infrastructure for AI, cloud and hybrid cloud, and advances technologies in high-growth markets. With a talented team and a strategic global network, Celestica helps its customers achieve competitive advantages. For more information on Celestica, visit www.celestica.com. Our securities filings can be accessed at www.sedarplus.ca and www.sec.gov.

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release relating to Celestica’s future plans, expectations, beliefs, and intentions are “forward-looking statements” and are subject to material risks, uncertainties, and assumptions. Those statements may include statements related to strong growth trajectory and sustainable, multi-year growth, and expected benefits of leadership appointments, including driving operational velocity, scaling the business effectively and capturing accelerating demand across end markets, all of which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, and Canadian securities laws. Forward-looking statements are commonly identified by words such as “would,” “may,” “expects,” “believes,” “designed to” “intends,” “position for” and other terms with similar meaning. Investors are cautioned that the forward-looking statements in this press release are based on current beliefs, assumptions and expectations, speak only as of the date of this press release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. Such statements are subject to certain known and unknown risks and uncertainties, many of which are difficult to predict and are generally beyond Celestica’s control, that could cause actual results and other future events to differ materially from those expressed in, or implied or projected by, the forward-looking information. Investors are urged to review in detail the risks, uncertainties, and assumptions contained in Celestica’s Securities and Exchange Commission (SEC) filings, including Celestica’s most recent reports on Form 10-K, Form 10-Q, Current Reports on Form 8-K and other documents filed with, or furnished to, the SEC, and the Canadian Securities Administrators. These filings are available on the SEC’s website, and www.sedarplus.ca or on Celestica’s website at https://corporate.celestica.com/sec-filings. Celestica undertakes no duty to update any statement in light of new information or future events or otherwise, except as expressly required by applicable law.

Celestica Contacts:
Celestica Global Communications
(416) 448-2200
media@celestica.com

Celestica Investor Relations
clsir@celestica.com

Company begins trading under HLSQ; completes rebrand to become an integrated platform serving digital infrastructure, energy, critical infrastructure and homeland security

NETANYA, Israel, Sept. 11, 2026 (GLOBE NEWSWIRE) — Tessera Defense and Homeland Security Inc. (NYSE American: HLSQ), formerly BiomX Inc. (NYSE American: PHGE) (“Tessera” or the “Company”), today announced that its corporate name and ticker symbol changes are now effective, completing its rebrand as a physical security technology platform.

The Company’s common stock will begin trading under the symbol “HLSQ” on the NYSE American at the market open on Friday September 11, 2026. Trading will continue without interruption, and no action is required by stockholders in connection with the name and symbol change.

The rebrand comes as governments and organizations face increasing pressure to protect the infrastructure, systems and sites upon which modern society depends. Recent attacks and suspected acts of sabotage affecting power infrastructure across Europe, incidents involving energy and transportation infrastructure in Germany, and the heightened protection of critical infrastructure across Poland and the Baltic states have placed physical security firmly on the international agenda.

Tessera provides a unified security platform that connects cameras, sensors, detection technologies, artificial intelligence and other systems, and offers solution design as well as advisory capabilities to address customers’ evolving physical security needs. The platform is designed to detect threats, understand events as they unfold and coordinate response in real time, supporting security teams, security managers and chief security officers across complex environments. The Company serves customers across homeland security, critical infrastructure, as well as enterprise organizations seeking advanced physical security capabilities.

Modern threats often cross traditional security boundaries, while protective systems remain disconnected, offering only isolated alerts. By converting fragmented data into unified, real-time insights, Tessera’s solution, tailored to each site’s specific needs, enables security teams to see a site as a whole rather than as a series of separate alerts. Tessera also offers security experts to audit sites so the platform can be used to its full potential and enable security teams to have full situational awareness of their environment.

“The name Tessera reflects both how our platform works and how we’re building the Company,” said Michael Oster, CEO of Tessera. “A tessera is an individual tile that becomes part of a larger mosaic. In the same way, we’re bringing together complementary technologies across detection, intelligence and response to create one integrated security platform. As threats become more complex, national security and infrastructure protection personnel need to understand what is happening and coordinate action faster and more accurately. Tessera is designed to help them make quicker, better-informed decisions to protect people and keep critical systems and sites secure.” 

Tessera’s capabilities include the AI-powered security intelligence technology of its subsidiary Zorronet and the LADAR-based detection systems of its subsidiary DFSL, supporting an integrated approach to advanced sensing, real-time intelligence and autonomous response.

The name change takes effect on the 25th anniversary of the September 11 attacks, a date the Company selected in remembrance of all those who were lost, including the hundreds of first responders who gave their lives while working to save others.  

About Tessera Defense and Homeland Security Inc. (Formerly BiomX Inc.)

Tessera Defense and Homeland Security Inc. (NYSE American: HLSQ) is a physical security technology company providing integrated, bespoke security solutions that connect detection, intelligence and response across complex security environments. The Tessera platform integrates cameras, sensors, detection technologies, AI and other security infrastructure to identify threats, understand events and coordinate response in real time. Tessera provides the technology, hardware and implementation expertise needed to tailor security solutions to the specific requirements of each site, helping customers deploy and optimize integrated security systems across critical infrastructure, energy, digital infrastructure and homeland security applications. 

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, platform, capabilities, portfolio, target markets, and the anticipated benefits of bringing complementary technologies together within an integrated security platform. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties, including risks related to the Company’s ability to execute its strategy, integrate and commercialize its technologies, achieve market acceptance, and those risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, as supplemented by the Form 10-K/A filed with the SEC on April 30, 2026, the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Actual results may differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statement, except as required by law. 

Media Contact: 

Yair Ohayon 
IR & Communication Manager
Yairo@thlsq.ai 

Six-Decade-Old Florida and Georgia Brokerage Makes Bond’s AI-Powered Preventative Personal Security Standard for Every Agent, Companywide

Bond Estimates U.S. Real Estate Market Opportunity at Over $300 Million Annually

Companywide Rollout Launches During REALTOR® Safety Month to Support the Safety of Real Estate Professionals 

NEW YORK and JACKSONVILLE, Fla., Sept. 11, 2026 (GLOBE NEWSWIRE) — Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s first AI-powered Preventative Personal Security platform adopted by leading multinational companies, today announced that it has teamed up with Watson Realty Corp. (“Watson”), one of the largest and longest-established independent residential real estate brokerages in the Southeast, to provide Bond’s personal security services to approximately 800 real estate agents across Florida and Georgia. The companywide rollout launches this month to coincide with REALTOR® Safety Month, the National Association of REALTORS®’ (“NAR”) annual September initiative dedicated to the safety of real estate professionals.

Founded in 1965 and headquartered in Jacksonville, Florida, Watson has grown over six decades into a network of approximately 40 offices serving Northeast and Central Florida and Southeast Georgia, complemented by affiliated mortgage and title operations. Under the agreement, Bond becomes a standard resource for every Watson agent – provided by the company, not purchased individually – making Watson among the first brokerages of its size in the United States to extend professional, 24/7 personal security to its entire agent population.

Real estate is one of many professions in which working alone with strangers is an inherent part of the job. Agents routinely meet unfamiliar individuals for the first time, show vacant properties, host open houses and travel to unfamiliar locations, often outside business hours. According to NAR’s 2024 Member Safety Report, more than one in five REALTORS® (22%) have experienced a situation that made them fear for their personal safety. Bond is designed for exactly the moments that fall between “everything is fine” and “call 911”: with a single tap, an agent can have a live Bond Personal Security Agent monitor a showing or open house in real time, track their trip to and from a property, check in if they fail to arrive as expected, help de-escalate a situation, and coordinate with first responders if it becomes an emergency.

“Our agents are the heart of this company. They spend much of their working lives away from an office, meeting people for the first time and walking into properties alone, and we believe they should have professional security resources available to them wherever their work takes them,” said William Watson III, President of Watson Realty Corp. “Bond has created a new reality. For the first time, our agents don’t have to wait until it’s an emergency to get help, and Bond agents can even deter threats before they ever become emergencies. I felt an obligation to do this for my people.”

“We’re proud to now be able to identify Watson as our partner in this previously-announced deal. Revolutions require new technologies and operating models, but also leaders who can look ahead and see what is coming next. Watson has been a leader in Southeastern real estate for more than sixty years, and Bill’s decision to make Bond standard for every agent, companywide, says a great deal about how seriously he takes the people who carry his name into the field every day,” said Doron Kempel, Founder and CEO of Bond. “The workplace no longer ends at the office door, and neither should an employer’s commitment to its people. Real estate is a clear example of a large, distributed workforce that is an opportunity for Bond to enhance peace of mind for millions of people, and we believe Watson’s leadership sets a standard that brokerages across the country will follow.”

Watson is the leading Southeastern real estate company referenced in Bond’s August 20, 2026 announcement of its entry into the U.S. real estate market. With more than 1.4 million REALTORS® represented by NAR, Bond continues to estimate the real estate market opportunity for its platform at over $300 million annually in the United States and over $1.5 billion globally. The Watson deployment also illustrates the operating leverage of Bond’s enterprise distribution model, in which a single organizational relationship adds hundreds of covered individuals and recurring subscriptions at once, and which Bond believes can be replicated efficiently across other large, distributed workforces that operate outside a traditional office.

About Watson Realty Corp.

Founded in 1965 by William A. Watson, Jr., Watson Realty Corp. is one of the largest independent, family-led residential real estate brokerages in the Southeast, serving communities throughout Northeast and Central Florida and Southeast Georgia through approximately 40 offices and affiliated mortgage and title services. For more than six decades, Watson has maintained a longstanding focus on service, professionalism and support for its agents and customers. Additional information is available at www.watsonrealtycorp.com.

About Bond

Bond is an international company headquartered in New York City — with command centers around the world — that is redefining personal security through its AI-powered Preventative Personal Security platform. The company has invested more than $100 million to date in its technology, operations, and global expansion.

Bond offers personal security to more people than any other company globally. Bond is trusted by leading corporations, cities, and universities, and has already supported more than 1.25 million security service requests, including over 10,000 emergencies and life-saving interventions. Bond operates in 28 countries and growing, positioning itself as a new global standard for personal security and peace of mind. Additional information about the Company is available at: www.ourbond.com.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading “Risk Factors” in our most recent Registration Statement on Form S-1, under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K, or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC, copies of which are available on the SEC’s website at www.sec.gov. Our Bond, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise that occur after the date of this release, except as required by law.

Contact:
Crescendo Communications, LLC
212-671-1020
OBAI@crescendo-ir.com

Clermont-Ferrand, September 11th, 2026

COMPAGNIE GÉNÉRALE DES ÉTABLISSEMENTS MICHELIN

Partnership Limited by Shares (commandite par actions) having a capital of EUR 343,803,187
Registered in the CLERMONT-FERRAND Trade and companies register under number 855 200 887
Head office: 23, place des Carmes-Déchaux – 63000 Clermont-Ferrand, France

Disclosure of the total number of voting rights and of the number of shares making up the Company’s capital
(Articles L.233-8 of the French Commercial Code and 223-16 of the General Reglementation of the Autorité des Marchés Financiers)

Date Number of shares Total number of voting rights
 

2026/08/31

 

687,606,374

 

Number of theoretical voting rights : 977,754,802

 

Number of voting rights : 962,487,664*

 

              *Considering 15,267,138 treasury shares

             Contact details

Investor Relations

 

investor-relations@michelin.com

 

Guillaume Jullienne

 

guillaume.jullienne@michelin.com

 

Benjamin Marcus
benjamin.marcus@michelin.com

 

Nadia Ait-Mokhtar
nadia.ait-mokhtar@michelin.com

 

Media Relations

 

+33 (0) 1 45 66 22 22

 

groupe-michelin.service-de-presse@michelin.com

 

Individual Shareholders

 

+33 (0) 4 73 32 23 05

 

Muriel Combris-Battut
muriel.combris-battut@michelin.com

 

Elisabete Antunes
elisabete.antunes@michelin.com

DISCLAIMER

This press release is not an offer to purchase or a solicitation to recommend the purchase of Michelin shares. To obtain more detailed information on Michelin, please consult the documents filed in France with the Autorité des Marchés Financiers, which are also available from the michelin.com website.
This press release may contain a number of forward-looking statements. Although the Company believes that these statements are based on reasonable assumptions at the time of publishing this document, they are by nature subject to risks and contingencies liable to translate into a difference between actual data and the forecasts made or inferred by these statements.

Attachment

 

TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor using its proprietary DRP® technology, announced that Allarity Acquisition Corp., a newly formed special purpose acquisition company (SPAC), has publicly filed a Registration Statement on Form S-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its units.

The proposed initial public offering is expected to have a base offering size of $100 million, or $115 million if the underwriters exercise their over-allotment option in full. Under the terms of the proposed offering, ALLR Sponsor LLC, a wholly-owned subsidiary of Allarity, is the sponsor of Allarity Acquisition Corp.   ALLR Sponsor LLC is expected to own approximately 25.0% of Allarity Acquisition Corp.’s issued and outstanding ordinary shares following completion of the offering, subject to the terms described in the Registration Statement.

Allarity Acquisition Corp. may pursue an initial business combination in any industry, sector or geographic region. Jesper Hoiland, a current board member of Allarity and a former EVP and President of Novo Nordisk, will serve as Chairman of the board of directors of Allarity Acquisition Corp.

Allarity Acquisition Corp. has applied to list its units on Nasdaq under the symbol “ALLNU.” Allarity Acquisition Corp. was formed for the purpose of completing an asset or other acquisition, a merger, share exchange, share purchase, or similar business combination with one or more businesses. Following separation from ALLR, the Class A ordinary shares and warrants are expected to trade under the symbols “ALLN” and “ALLNW,” respectively.

The offering does not change Allarity’s previously disclosed expectation that it has sufficient working capital to fund its operations into the summer of 2028.

Maxim Group LLC is acting as sole book-running manager for Allarity Acquisition Corp.’s initial public offering.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus related to the proposed initial public offering by Allarity Acquisition Corp. may be obtained for free by visiting the SEC’s website at www.sec.gov or from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at (212) 895-3745.

The Registration Statement, including a prospectus, which is preliminary and subject to completion, relating to the securities of Allarity Acquisition Corp. has been filed with the SEC but has not yet become effective. The securities may not be sold nor may offers to buy may be accepted, prior to the time Registration Statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.

About Stenoparib/2X-121

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Tankyrases have emerged as potential therapeutic targets in cancer due in part to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, including drug-resistant cancers. Through its inhibition of PARP and the WNT signaling pathway, stenoparib has the potential to provide therapeutic benefit across multiple cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer.

Allarity has secured exclusive global rights to develop and commercialize stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known as E7449 and 2X-121.

Allarity has completed its first Phase 2 trial evaluating stenoparib in patients with advanced ovarian cancer. The trial demonstrated promising and durable clinical benefit in patients with ovarian cancer who received two or more prior lines of therapy and were treated with stenoparib twice daily. Updated data from the trial were presented at the AACR Special Conference on Advances in Ovarian Cancer in September 2025. These analyses remain subject to change as the study data mature.

Based on the emerging clinical experience with stenoparib, Allarity developed a new protocol focused on patients with platinum-resistant ovarian cancer, which began enrolling patients in the summer of 2025. The amended protocol enrolls only platinum-resistant or platinum-ineligible patients and is designed to advance the clinical development of stenoparib toward potential FDA approval.

In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for patients with relapsed small cell lung cancer, or SCLC, began enrolling in early 2026 and is currently enrolling patients at multiple U.S. Department of Veterans Affairs sites.

About the Drug Response Predictor – DRP® Companion Diagnostic

Allarity uses its drug-specific DRP® technology to identify patients who, based on the gene expression signature of their cancer, may be more likely to benefit from a particular drug. By screening patients before treatment, and selecting those with a sufficiently high, drug-specific DRP score, the DRP technology is designed to increase the likelihood of therapeutic benefit.

The DRP methodology is based on the comparisons of sensitive and resistant human cancer cell lines, and incorporates transcriptomic data, clinical tumor biology filters and prior clinical trial outcomes. The DRP uses messenger RNA expression profiles derived from patient biopsies to generate drug-specific predictive scores.

The DRP® platform has demonstrated the ability to provide statistically significant predictions of clinical outcome following drug treatment across dozens of retrospective and prospective clinical studies. The platform is designed for potential application across multiple cancer types, is patented for dozens of anti-cancer drugs and has been extensively described in peer-reviewed scientific literature.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements reflect current expectations or forecasts regarding future events. The words “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the proposed initial public offering by Allarity Acquisition Corp., including the anticipated size, structure, terms, timing and completion of the offering; the effectiveness of the registration statement; the proposed Nasdaq listing and anticipated commencement of trading; the expected ownership interest of ALLR Sponsor LLC following the offering; and Allarity Acquisition Corp.’s ability to identify and complete a suitable initial business combination. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the possibility that the registration statement may not become effective, Nasdaq may not approve the proposed listing, or the proposed offering may be delayed, modified, reduced or abandoned; changes in the proposed size, structure or terms of the offering or the expected ownership interest of ALLR Sponsor LLC; the risk that Allarity’s at-risk investment may be lost or may exceed current expectations; the inability of Allarity Acquisition Corp. to identify or complete a suitable initial business combination within the required period; shareholder redemptions, dilution, conflicts of interest and other risks associated with SPAC structures; and the potential diversion of management time and resources; and the clinical, regulatory, manufacturing, financing and commercialization risks associated with stenoparib and the stenoparib-specific DRP® companion diagnostic. For a discussion of risks and uncertainties and other important factors that could cause actual results to differ materially from those contained in the forward-looking statements, see the risk factors and other disclosures in Allarity’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings are available through the SEC’s website. All information in this press release is as of the date of the release, and the Company undertakes no obligation to update or revise this information, except as required by applicable law.

###

Company Contact:         
        investorrelations@allarity.com

        
Media Contact:
        Thomas Pedersen
        Carrotize PR & Communications
        +45 6062 9390
        tsp@carrotize.com

Attachment

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that Marc Rowan, Chief Executive Officer and Chair of the board of Apollo, will participate in a fireside chat at the Bank of America 31st Annual Financials CEO Conference on Wednesday, September 23, 2026 at 6:00 am EDT.

A live webcast of the event will be available on Apollo’s Investor Relations website at ir.apollo.com. For those unable to join live, a replay will be available shortly after the event.

About Apollo

Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Our patient, creative, and knowledgeable approach to investing aligns our clients, businesses we invest in, our employees, and the communities we impact, to expand opportunity and achieve positive outcomes. As of June 30, 2026, Apollo had approximately $1.05 trillion of assets under management. To learn more, please visit www.apollo.com.

Contacts

Noah Gunn
Global Head of Investor Relations
Apollo Global Management, Inc.
(212) 822-0540
IR@apollo.com

Joanna Rose
Global Head of Corporate Communications
Apollo Global Management, Inc.
(212) 822-0491
Communications@apollo.com

New York, Sept. 11, 2026 (GLOBE NEWSWIRE) — Columbus Acquisition Corp (the “Company”), a blank check company, today announced that it convened its Extraordinary General Meeting of the Shareholders (the “Meeting”) and immediately adjourned the Meeting, without conducting any business.

The Meeting was adjourned as to all of the proposals contained in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on August 19, 2026, including any amendments or supplements thereto (the “Proxy Statement”), including the proposal to approve the proposed business combination with WISeSat.Space Corp.

The Company will announce the date of the reconvened Meeting, and a new redemption deadline (the “Extended Redemption Deadline”), in the coming days. Public shareholders seeking to exercise their redemption rights must complete the procedures described in the Proxy Statement by the Extended Redemption Deadline. As of September 8, 2026, there was approximately $10.66 per share in trust.

The record date for determining the Company shareholders entitled to receive notice of and to vote at the Meeting remains the close of business on August 17, 2026 (the “Record Date”). Shareholders as of the Record Date are eligible to vote, even if they have subsequently sold their shares.
  
If you have already voted, you do not need to vote again unless you would like to change or revoke your prior vote on any proposal.

If you have already submitted a proxy and do not wish to change your vote, you need not take any further action. If you have submitted a proxy and wish to change your vote, you may revoke your proxy at any time before it is exercised at the Meeting as provided in the Proxy Statement. Please note, however, that if your shares are held in street name by a broker or other nominee and you wish to revoke a proxy, you must contact the broker or nominee to revoke any prior voting instructions.

The Company’s shareholders who have questions regarding the adjournment, or the Meeting, or would like to request documents may contact the Company’s proxy solicitor, Advantage Proxy, Inc., at:

Advantage Proxy, Inc. P.O. Box 10904
Yakima, WA 98909
Individuals call toll-free 1-877-870-8565
Banks and brokers call 1-206-870-8565
Email: ksmith@advantageproxy.com

In addition, shareholders who have already submitted a redemption request with respect to the shares held by them may withdraw such request by contacting our transfer agent. If you would like to change or revoke your prior vote on any proposal, or reverse a redemption request, please refer to the Proxy Statement for additional information on how to do so.

In connection with the adjournment of the Meeting and the extension of the redemption deadline, the Company is concurrently filing with the Securities and Exchange Commission (“SEC”) definitive additional materials on Schedule 14A, consisting of a supplement dated September 11, 2026 (the “Supplement”) to the Proxy Statement. Shareholders are encouraged to read the Supplement together with the Proxy Statement.

About Columbus Acquisition Corp

Columbus Acquisition Corp is a blank check company, also commonly referred to as a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. Columbus is led by Fen “Eric” Zhang, Chairman and Chief Executive Officer, and Jie “Janet” Hu, Chief Financial Officer, who are growth-oriented executives with a long track record of value creation across industries. 

Forward Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including but not limited to the date of the Meeting, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Additional Information and Where to Find It

On August 19, 2026, the Company filed a definitive proxy statement with the SEC in connection with its solicitation of proxies for the Meeting. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER DOCUMENTS THE COMPANY FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the definitive proxy statement (including any amendments or supplements thereto) and other documents filed with the SEC through the website maintained by the SEC at www.sec.gov or by contacting the Company’s proxy solicitor.

Participants in the Solicitation

The Company and its respective directors and officers may be deemed to be participants in the solicitation of proxies from shareholders in connection with the Meeting. Additional information regarding the identity of these potential participants and their direct or indirect interests, by security holdings or otherwise, is set forth in the definitive proxy statement. You may obtain free copies of these documents using the sources indicated above.

Contact

Fen Zhang
Chairman and Chief Executive Officer
Email: eric.zhang@herculescapital.group
Tel: (+1) 949 899 1827 

SAN FRANCISCO, CALIFORNIA, Sept. 11, 2026 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary TriKE® natural killer (NK) cell engager platform, will host a live company presentation on the development of the TriKE® platform for cancer treatment today, September 11, 2026, at 2:00 p.m. Eastern Time.

The webinar will feature Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, and Dr. Jeffrey Miller, MD1, Consulting Senior Medical Director, who will discuss clinical progress in blood cancers and solid tumors, insights from increasing dose levels, the platform’s competitive positioning, and key milestones ahead.

Webinar Information:
Title: The TriKE® Platform, Clinical Progress, and the Case for NK Cell Immunotherapy
Date: Friday, September 11, 2026
Time: 2:00 p.m. Eastern Time
Webcast: Please click here to register.

A replay of the webcast will be made available at gtbiopharma.com following the event.

About GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “endeavors,” “strives,” “may,” or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.

TriKE® is a registered trademark owned by GT Biopharma, Inc.

Investor Relations Contact:

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577

LinkedIn |Facebook |X |Instagram | YouTube

1 Dr. Miller is the Consulting Senior Medical Director at GT Biopharma and holds stock and options in GTBP.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.